## SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 25, 2003

HAEMONETICS CORPORATION
(Exact Name of Registrant as Specified in its Charter)

Massachusetts 1-10730 04-2882273

(State or other jurisdiction of incorporation or organization) Number) (IRS Employer Identification Number)

400 Wood Road
Braintree, MA 02184
(Address of principal executive (Zip Code)
offices)

Registrant's telephone number, including area code (781) 848-7100

Item 5. Other Events and Regulation FD Disclosure

On August 25, 2003, Haemonetics Corporation (the "Company") announced the election of Lawrence C. Best, Senior Vice President and Chief Financial Officer of Boston Scientific Corporation, to its Board of Directors. The election was effective as of August 22, 2003.

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press Release of the Company dated August 25, 2003.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

Date: August 25, 2003 By: /s/Ronald J. Ryan

Ronald J. Ryan, Senior Vice President and Chief Financial

Officer

Exhibit 99.1

FOR RELEASE:

Date: August 25, 2003

Time: 10:00 a.m.

CONTACT: Lisa Lopez

Tel. (781) 356-9457

Alternate Tel. (617) 320-2401

fallon@haemonetics.com

Haemonetics Elects Boston Scientific CFO to Its Board of Directors

BRAINTREE, MA, August 25, 2003 - Haemonetics Corporation (NYSE:HAE) today announced that Lawrence C. Best, Senior Vice President and Chief Financial Officer of Boston Scientific Corporation, has been elected to the Haemonetics Board of Directors. The election was effective as of August 22, 2003.

Mr. Best has served as Senior Vice President and Chief Financial Officer for Boston Scientific since 1992. Prior to his work with Boston Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. He also served a two-year fellowship at the Securities and Exchange Commission from 1979 to 1981 and a one-year term as a White House-appointed Presidential Exchange Executive in Washington, D.C. Mr. Best also serves as a member of the Board of Directors of Biogen, Inc.

Ronald A. Matricaria, Chairman of Haemonetics, said, "Larry brings an impressive record of financial discipline and a strong understanding of the issues facing medical device companies. He has been a key member of the Boston Scientific executive team that is credited with building one of the market leading companies in the medical device industry. We are delighted he agreed to serve on our board, and as a member of the Audit Committee."

Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics' products and markets, visit the Company's web site at http://www.haemonetics.com.